# US 2021/0277128 A1 · Bispecific Tetravalent Antibodies and Methods of Making and Using Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277128 A1
- Document ID: US20210277128A1
- Status: Published application
- Kind: A1
- Application number: 17/143,204
- Filed: 2021-01-07
- Published: 2021-09-09
- Earliest claimed: 2014-12-22
- Assignees: Systimmune, Inc.; Sichuan Baili Pharmaceutical Co. Ltd.
- Applicants: SystImmune, Inc.; Sichuan Baili Pharmaceutical Co. Ltd.
- Inventors: Zeren Gao; Phil Tan; Brian R. Kovacevich; Blair R. Renshaw; Jeffrey B. Adamo; Nga Sze Amanda Mak; Shi Zhuo; Lan Chen; Yi Zhu
- Web page: https://patentgrep.com/patent/US20210277128A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61P 35/00: Antineoplastic agents
- C07K 14/70521: {CD28, CD152}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07K 14/71: for growth factors; for growth regulators
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different members of EGFR family.

## Claims

### Claim 1

A bispecific tetravalent antibody, said bispecific tetravalent antibody comprising:
two IgG1 heavy chains;
two kappa light chains; and
two single chain Fv (scFv) domains;
wherein the two IgG1 heavy chains and kappa light chains form an IgG moiety with a binding specificity to a first member of the EGFR family;
wherein the two scFv domains have a binding specificity to a second member of the EGFR family, and each scFv domain is connected to the C-terminus of either of the IgG1 heavy chains by a connector with an amino acid sequence of (gly-gly-gly-gly-ser)n, to provide a IgG1-connector connection, wherein n is an integral of at least 1; and
wherein each scFv domain has a structure order of N terminus-variable heavy chain-linker-variable light chain-C terminus or N-terminus-variable light chain-linker-variable heavy chain-C-terminus, and wherein the linker is comprised of amino acid sequence of (gly-gly-gly-gly-ser)m, wherein m is an integral of at least 3.

### Claim 2 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein n is an integral between 1 to 10.

### Claim 3 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein m is 3, 4, 5, or 6.

### Claim 4 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein at least one of the IgG1 heavy chains is a humanized or human IgG1 heavy chain.

### Claim 5 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein both IgG1 heavy chains are humanized or human IgG1 heavy chains.

### Claim 6 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein at least one of the kappa light chains is a humanized or human kappa light chain.

### Claim 7 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein both kappa light chains are humanized or human kappa light chains.

### Claim 8 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the first or the second member of the EGFR family comprises HER3, EGFR, a fragment or a derivative thereof.

### Claim 9 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the first or the second member of the EGFR family is independently selected from a group consisting of HER3, EGFR, a fragment or a derivative thereof.

### Claim 10 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for HER3.

### Claim 11 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the scFv domains have a binding specificity for EGFR.

### Claim 12 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for HER3 and the scFv domains have a binding specificity for EGFR simultaneously.

### Claim 13 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for EGFR,

### Claim 14 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the scFv domains have a binding specificity for HER3.

### Claim 15 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for EGFR and the scFv domains have a binding specificity for HER3 simultaneously.

### Claim 16 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the C terminus of at least one of the IgG1 heavy chains misses an amino acid residue.

### Claim 17 (depends on 16)

The bispecific tetravalent antibody of claim 16, wherein the amino acid residue is a lysine.

### Claim 18 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG1-connector connection is resistant to protease activity.

### Claim 19 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein at least one of the IgG1 heavy chains comprises two mutations in the CH3 domain, and wherein the two mutations are reversion to the common residues in human CH3 domain.

### Claim 20 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein at least one of the IgG1 heavy chains comprises an amino acid comprising SEQ ID NO 7, 15, 23, 31, 39, 47, and 127.

### Claim 21 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG1 heavy chain, connector, and scFv domain have an amino acid comprising SEQ ID NO 56, 66, 76, 86, 98, 108, 118, and 136.

### Claim 22 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein at least one of the kappa light chains comprises an amino acid sequence comprising SEQ ID NO 3, 11, 19, 27, 35, 43, 51, 61, 71, 81, 92, 103, 113, 123, and 131.

### Claim 23 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein at least one of variable light chain comprises an amino acid sequence comprising SEQ ID NO 4, 12, 20, 28, 36, 44, 52, 62, 72, 82, 93, 104, 114, 124, and 132.

### Claim 24 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein at least one of variable heavy chain comprises an amino acid sequence comprising SEQ ID NO 8, 16, 24, 32, 40, 48, 57, 67, 77, 87, 99, 109, 119, 128, and 137.

### Claim 25 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for HER3, and the scFv domains have a binding specificity for EGFR;
wherein the IgG1 heavy chain, connector, and scFv domain have an amino acid sequence of SEQ ID NO 56, and the kappa light chain has an amino acid sequence of SEQ ID NO 51.

### Claim 26 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for HER3, and the scFv domains have a binding specificity for EGFR;
wherein the IgG1 heavy chain, connector, and scFv domain have an amino acid sequence of SEQ ID NO 76, and the kappa light chain has an amino acid sequence of SEQ ID NO 71.

### Claim 27 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for HER3, and the scFv domains have a binding specificity for EGFR;
wherein the IgG1 heavy chain, connector, and scFv domain have an amino acid sequence of SEQ ID NO 108, and the kappa light chain has an amino acid sequence of SEQ ID NO 103.

### Claim 28 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for EGFR, and the scFv domains have a binding specificity for HER3;
wherein the IgG1 heavy chain, connector, and scFv domain have an amino acid sequence of SEQ ID NO 66, and the kappa light chain has an amino acid sequence of SEQ ID NO 61.

### Claim 29 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for EGFR, and the scFv domains have a binding specificity for HER3;
wherein the IgG1 heavy chain, connector, and scFv domain have an amino acid sequence of SEQ ID NO 86, and the kappa light chain has an amino acid sequence of SEQ ID NO 81.

### Claim 30 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for EGFR, and the scFv domains have a binding specificity for HER3;
wherein the IgG1 heavy chain, connector, and scFv domain have an amino acid sequence of SEQ ID NO 98, and the kappa light chain has an amino acid sequence of SEQ ID NO 92.

### Claim 31 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for EGFR, and the scFv domains have a binding specificity for HER3;
wherein the IgG1 heavy chain, connector, and scFv domain have an amino acid sequence of SEQ ID NO 118, and the kappa light chain has an amino acid sequence of SEQ ID NO 113.

### Claim 32 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the IgG moiety has a binding specificity for EGFR, and the scFv domains have a binding specificity for HER3;
wherein the IgG1 heavy chain, connector, and scFv domain have an amino acid sequence of SEQ ID NO 136, and the kappa light chain has an amino acid sequence of SEQ ID NO 131.

### Claim 33 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the antibody inhibits cancer cell growth.

### Claim 34 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the antibody binds to EGRF and HER3 with a Kd less than 50 nM.

### Claim 35 (depends on 1)

The bispecific tetravalent antibody of claim 1, wherein the antibody simultaneously binds to EGRF with a Kd less than 50 nM and binds to HER3 with a Kd less than 50 nM.

### Claim 36 (depends on 1)

An IgG1 heavy chains for the bispecific tetravalent antibody of claim 1, comprising an amino acid sequences selected from SEQ ID NO 7, 15, 23, 31, 39, 47, and 127

### Claim 37 (depends on 1)

A kappa light chain for the bispecific tetravalent antibody of claim 1, comprising an amino acid sequence selected from SEQ ID NO 3, 11, 19, 27, 35, 43, 51, 61, 71, 81, 92, 103, 113, 123, and 131.

### Claim 38 (depends on 1)

A variable light chain for the bispecific tetravalent antibody of claim 1, comprising an amino acid sequence selected from SEQ ID NO 4, 12, 20, 28, 36, 44, 52, 62, 72, 82, 93, 104, 114, 124, and 132

### Claim 39 (depends on 1)

A variable heavy chain for the bispecific tetravalent antibody of claim 1, comprising an amino acid sequence selected from SEQ ID NO 8, 16, 24, 32, 40, 48, 57, 67, 77, 87, 99, 109, 119, 128, and 137.

### Claim 40 (depends on 1, 36, 37, 38, 39)

An isolated nucleic acid encoding the antibody of claim 1, the IgG1 heavy Chain of claim 36, the kappa light chain of claim 37, the variable light chain of claim 38, or the variable heavy chain of claim 39.

### Claim 41 (depends on 40)

An expression vector comprising the isolated nucleic acid of claim claim 40.

### Claim 42 (depends on 41)

The expression vector of claim 41, wherein the vector is expressible in a cell.

### Claim 43 (depends on 40)

A host cell comprising the nucleic acid of claim 40.

### Claim 44 (depends on 43)

A host cell comprising the expression vector of claim 43.

### Claim 45 (depends on 44)

The host cell of claim 44, wherein the host cell is a prokaryotic cell or a eukaryotic cell.

### Claim 46 (depends on 43, 44, 45)

A method of producing an antibody comprising culturing the host cell of one of claims 43-45 so that the antibody is produced.

### Claim 47 (depends on 1)

An immunoconjugate comprising the antibody of claim 1 and a cytotoxic agent.

### Claim 48 (depends on 1)

A pharmaceutical composition, comprising the bispecific tetravalent antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 49 (depends on 48)

The pharmaceutical composition of claim 48, further comprising radioisotope, radionuclide, a toxin, a therapeutic agent, a chemotherapeutic agent or a combination thereof.

### Claim 50 (depends on 47)

A pharmaceutical composition, comprising the immunoconjugate of claim 47 and a pharmaceutically acceptable carrier.

### Claim 51 (depends on 1)

A method of treating a subject with a cancer, comprising administering to the subject an effective amount of the bispecific tetravalent antibody of claim 1.

### Claim 52 (depends on 51)

The method of claim 51, wherein the cancer comprises cells expressing at least two members of EGFR family.

### Claim 53 (depends on 51)

The method of claim 51, wherein the cancer comprises breast cancer, colorectal cancer, pancreatic cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, non-small lung cell cancer, glioma, esophageal cancer, nasopharyngeal cancer, anal cancer, rectal cancer, gastric cancer, bladder cancer, cervical cancer, or brain cancer.

### Claim 54 (depends on 51)

The method of claim 51, further comprising co-administering an effective amount of a therapeutic agent.

### Claim 55 (depends on 54)

The method of claim 54, wherein the therapeutic agent comprises an antibody, a chemotherapy agent, an enzyme, or a combination thereof.

### Claim 56 (depends on 54)

The method of claim 54, wherein the therapeutic agent comprises an anti-estrogen agent, a receptor tyrosine inhibitor, or a combination thereof.

### Claim 57 (depends on 54)

The method of claim 54, wherein the therapeutic agent comprises capecitabine, cisplatin, trastuzumab, fulvestrant, tamoxifen, letrozole, exemestane, anastrozole, aminoglutethimide, testolactone, vorozole, formestane, fadrozole, letrozole, erlotinib, lafatinib, dasatinib, gefitinib, imatinib, pazopinib, lapatinib, sunitinib, nilotinib, sorafenib, nab-palitaxel, a derivative or a combination thereof.

### Claim 58 (depends on 54)

The method of claim 54, wherein the therapeutic agent comprises a check point inhibitor.

### Claim 59 (depends on 54)

The method of claim 54, wherein the therapeutic agent comprises PD1, PDL1, CTLA4, 4-1BB, OX40, GITR, TIM3, LAG3, TIGIT, CD40, CD27, HVEM, BTLA, VISTA, B7H4, a derivative or a combination thereof.

### Claim 60 (depends on 51)

The method of claim 51, wherein the subject is a human.

### Claim 61 (depends on 1)

A method of inhibiting a biological activity of a HER receptor in a subject, comprising administering to the subject an effective amount of the antibody of claim 1 to inhibit a biological activity of a HER receptor.

### Claim 62 (depends on 1)

A solution comprising an effective concentration of the bispecific tetravalent antibody of claim 1, wherein the solution is blood plasma in a subject.
